{"disease":{"id":"small-intestinal-neoplasms","name":"small intestinal neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03817866","title":"Chromogranin A as Blood Marker in Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Brahms AG","has_results":false},{"nct_id":"NCT04752215","title":"A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}